• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, September 18, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Sugar pills relieve pain for chronic pain patients

Bioengineer by Bioengineer
September 12, 2018
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
  • Doctors should consider treating chronic pain patients with sugar pills
  • Placebo pills relieve pain as effectively as drugs for half of chronic pain patients
  • Pain reduced by 30 percent
  • No need to fool patients, brain is primed to respond
  • Finding can result in vast cost savings for patients, health care system

CHICAGO — Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology. And the pills will reduce their pain as effectively as any powerful drug on the market, according to new research.

Northwestern Medicine scientists have shown they can reliably predict which chronic pain patients will respond to a sugar placebo pill based on the patients' brain anatomy and psychological characteristics.

"Their brain is already tuned to respond," said senior study author A. Vania Apkarian, professor of physiology at Northwestern University Feinberg School of Medicine. "They have the appropriate psychology and biology that puts them in a cognitive state that as soon as you say, 'this may make your pain better,' their pain gets better."

There's no need to fool the patient, Apkarian said.

"You can tell them, 'I'm giving you a drug that has no physiological effect but your brain will respond to it,'" he said. "You don't need to hide it. There is a biology behind the placebo response."

The study was published Sept. 12 in Nature Communications.

The findings have three potential benefits:

  • Prescribing non-active drugs rather than active drugs. "It's much better to give someone a non-active drug rather than an active drug and get the same result," Apkarian said. "Most pharmacological treatments have long-term adverse effects or addictive properties. Placebo becomes as good an option for treatment as any drug we have on the market."
  • Eliminating the placebo effect from drug trials. "Drug trials would need to recruit fewer people, and identifying the physiological effects would be much easier," Apkarian said. "You've taken away a big component of noise in the study."
  • Reduced health care costs. A sugar pill prescription for chronic pain patients would result in vast cost savings for patients and the health care system, Apkarian said.

How the study worked

About 60 chronic back pain patients were randomized into two arms of the study. In one arm, subjects didn't know if they got the drug or the placebo. Researchers didn't study the people who got the real drug. The other study arm included people who came to the clinic but didn't get a placebo or drug. They were the control group.

The individuals whose pain decreased as a result of the sugar pill had a similar brain anatomy and psychological traits. The right side of their emotional brain was larger than the left, and they had a larger cortical sensory area than people who were not responsive to the placebo. The chronic pain placebo responders also were emotionally self-aware, sensitive to painful situations and mindful of their environment.

"Clinicians who are treating chronic pain patients should seriously consider that some will get as good a response to a sugar pill as any other drug," Apkarian said. "They should use it and see the outcome. This opens up a whole new field."

###

Other Northwestern authors are co-lead author Etienne Vachon-Presseau, Sara Berger, Taha Abdullah, Lejian Huang, Guillermo Cecchi, James Griffith and Thomas Schnitzer.

This study was funded by National Center for Complementary and Integrative Health grant AT007987 of the National Institutes of Health and the Canadian Institutes of Health Research and Fonds de Recherche Santé Québec.

More News at Northwestern Now

Find experts on our Faculty Experts Hub

Follow @NUSources for expert perspectives

http://news.feinberg.northwestern.edu/tag/press-release/

Media Contact

Marla Paul
[email protected]
@northwesternu

http://www.northwestern.edu

http://dx.doi.org/10.1038/s41467-018-05859-1

Share12Tweet7Share2ShareShareShare1

Related Posts

Unveiling Maladaptive Daydreaming Profiles in Chinese Youth

September 18, 2025

University of Houston Co-Leads $25 Million NIH Grant to Investigate Slowing Childhood Nearsightedness

September 18, 2025

New Study Identifies Top Three Deadliest Risk Factors for Common Liver Disease

September 18, 2025

IU Study Reveals Key Challenges in Identifying Patients’ Social Needs

September 18, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    155 shares
    Share 62 Tweet 39
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    67 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Unveiling Maladaptive Daydreaming Profiles in Chinese Youth

Breakthrough Study Highlights Potential of Combination Therapy to Combat Treatment Resistance in Glioblastoma

NRG Oncology PREDICT-RT Study Completes Enrollment, Evaluates Tailored Concurrent Therapy and Radiation for High-Risk Prostate Cancer

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.